Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9H3H5

UPID:
GPT_HUMAN

ALTERNATIVE NAMES:
GlcNAc-1-P transferase; N-acetylglucosamine-1-phosphate transferase

ALTERNATIVE UPACC:
Q9H3H5; O15216; Q86WV9; Q9BWE6

BACKGROUND:
The enzyme UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase, known alternatively as GlcNAc-1-P transferase, initiates the synthesis of dolichol-linked oligosaccharides, essential for N-glycoprotein biosynthesis. This process is vital for proper cell function and development.

THERAPEUTIC SIGNIFICANCE:
Linked to diseases such as congenital disorder of glycosylation 1J and myasthenic syndrome, congenital, 13, the enzyme's dysfunction underscores its importance in human health. Targeting UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase offers a promising avenue for therapeutic intervention.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.